
Acer’s shares drop 80% as FDA rejects drug for vascular Ehlers-Danlos syndrome
pharmafile | June 26, 2019 | News story | Research and Development, Sales and Marketing | Acer Therapeutics, Edsivo, pharma
Acer Therapeutics has seen its share value plunge by 80% after it emerged that the FDA had turned down its drug application for Edsivo (celiprolol) in the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
In the complete response letter sent to the firm by the US regulator, concerns were raised over the integrity of the clinical trial data submitted in support of the application.
The data submitted was derived from a study involving 53 participants with vEDS; upon analysis, the data demonstrated that Edsivo significantly reduced the risk of arterial dissection or rupture versus placebo.
In order to assuage these concerns over the drug’s efficacy, Acer will now be required to generate additional data for submission through new clinical trials to prove that the drug effectively reduces the risk of clinical events in vEDS patients.
“We remain committed to working closely with the FDA to fully understand its response,” said Chris Schelling, Acer’s Founder and CEO. “We expect to respond to the FDA in the third quarter of this year.”
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …






